Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Jounce Therapeutics Inc. (JNCE)

6.32   -0.19 (-2.92%) 07-07 16:00
Open: 6.42 Pre. Close: 6.51
High: 6.48 Low: 6.2
Volume: 214,073 Market Cap: 215M
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company offers vopratelimab, a clinical-stage monoclonal antibody that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors, which is in Phase II clinical trial for the treatment of PD-1/PD-L1 inhibitor patients with non-small cell lung cancer and urothelial cancer. It is also developing JTX-4014, a clinical-stage anti-PD-1 antibody for combination therapy; and JTX-1811, a monoclonal antibody designed to selectively deplete T regulatory cells in the tumor microenvironment that is in the IND-enabling phase. The company's product candidate includes JTX-8064, an antibody that binds to leukocyte immunoglobulin like receptor B2, which is a cell surface receptor expressed on macrophages. Jounce Therapeutics, Inc. was incorporated in 2012 and is headquartered in Cambridge, Massachusetts.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 6.716 - 6.76 6.76 - 6.8
Low: 6.341 - 6.397 6.397 - 6.448
Close: 6.424 - 6.512 6.512 - 6.591

Technical analysis

as of: 2020-07-07 3:36:04 PM
Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected.
Target: Six months: 8.14     One year: 9.45
Support: Support1: 5.15    Support2: 4.28
Resistance: Resistance1: 6.97    Resistance2: 8.09
Pivot: 6.67
Moving Average: MA(5): 6.58     MA(20): 6.43
MA(100): 5.20     MA(250): 5.17
MACD: MACD(12,26): 0.29     Signal(9): 0.37
Stochastic oscillator: %K(14,3): 42.67     %D(3): 47.82
RSI: RSI(14): 49.85
52-week: High: 10.00  Low: 2.79  Change(%): 47.7
Average Vol(K): 3-Month: 26572  10-Days: 32962

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
JNCE has closed above bottom band by 30.5%. Bollinger Bands are 14.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Fri, 03 Jul 2020
Hedge Funds Have Never Been This Bullish On Protara Therapeutics, Inc. (TARA) - Yahoo Finance

Fri, 26 Jun 2020
Jounce Therapeutics Inc. (NASDAQ:JNCE) is Holding Steady - The Oracle Dispatch

Tue, 23 Jun 2020
The Big Picture View: Jounce Therapeutics Inc. (JNCE) is down less than -23.25% year to date - Frisco Herald

Mon, 22 Jun 2020
Jounce Therapeutics Presents First Preclinical Data on Anti-CCR8 Antibody JTX-1811 and Vopratelimab Translational Data at The American Association for Cancer Research Virtual Annual Meeting - GlobeNewswire

Mon, 08 Jun 2020
Got $1,000? Buy These 4 Cancer Stocks - Motley Fool

Thu, 04 Jun 2020
Jounce Therapeutics Regains Worldwide Rights to JTX-8064 from Bristol Myers Squibb - GlobeNewswire

Financial Analysis

Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Click here to get more fundamental analysis.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  Nasdaq Global Select
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 34
Shares Float (M) 17
% Held by Insiders 12.88
% Held by Institutions 74.64
Shares Short (K) 1,450
Shares Short P. Month (K) 2,040

Stock Financials

EPS 1.240
EPS Est This Year -0.620
EPS Est Next Year -0.190
Book Value (p.s.) 4.480
Profit Margin 31.23
Operating Margin 28.58
Return on Assets (ttm) 12.3
Return on Equity (ttm) 34.6
Qtrly Rev. Growth
Gross Profit (p.s.) 3.583
Sales Per Share 4.020
EBITDA (p.s.) 1.261
Qtrly Earnings Growth
Operating Cash Flow (M) -30
Levered Free Cash Flow (M) -24

Stock Valuations

PE Ratio 5.07
PEG Ratio
Price to Book value 1.40
Price to Sales 1.56
Price to Cash Flow -7.02

Stock Dividends

Forward Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
Stock Chart
Stoxline Lite
Stoxline Pro
Option Calculator
(c) 2006-2020 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.